Physician profile
Caroline Sutherland
NPI 1063760056
$1,340.35
in general payments reported to CMS, 2019-2025
15 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $534 · 2022: $391 · 2023: $144 · 2024: $109 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $334.71 | 2021-2025 | Collagenase Santyl, Grafix Pl, Regranex |
| Sanara Medtech INC. | $183.97 | 2021 | |
| W. L. Gore & Associates, INC. | $116.78 | 2022 | |
| Boston Scientific Corporation | $111.63 | 2021-2025 | General - Therapies, Infinion 16 |
| Angiodynamics, INC. | $106.79 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.14 | 2025 | Caplyta |
| Kci USA, INC. | $66.05 | 2021-2022 | |
| Tactile Systems Technology INC | $63.27 | 2021-2022 | |
| Intuitive Surgical, INC. | $57.90 | 2022 | |
| Paratek Pharmaceuticals, INC. | $56.36 | 2023-2024 | Nuzyra |
| Abbvie INC. | $55.57 | 2022-2023 | |
| Davol INC. | $37.34 | 2023-2024 | Phasix Mesh |
| Bioventus LLC | $27.34 | 2022 | |
| Nabriva Therapeutics, Plc | $23.25 | 2022 | |
| Biowound Solutions, INC. | $11.25 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.